Shilpa Biologicals and SPIMACO Bio Partner to Advance Access to PD-1 Inhibitor Biosimilars in MENA Region

Shots: Shilpa Biologicals has entered into an exclusive MENA licensing & commercialization agreement with SPIMACO Bio for a portfolio of PD-1 inhibitor biosimilars used in cancer immunotherapy Shilpa Biologicals will lead exclusive development & manufacturing, with phased technology transfer to enable local biosimilar production in Saudi Arabia, while SPIMACO Bio will handle regulatory execution, market…

ByRidhi RastogiSeptember 15, 2026

NEWS

Novocure Reports MHLW’s Approval of Optune Lua for NSCLC

Shots: Approval of Optune Lua for adults with unresectable advanced/recurrent NSCLC who progressed on Pt-based regimen, was based on P-III (LUNAR) trial assessing it with PD-1/PD-L1 inhibitors or docetaxel (n=145) vs PD-1/PD-L1 inhibitors or docetaxel alone (n=146) Trial showed an mOS (1EP) of 13.2 vs 9.9mos. in the overall population, 19 vs 10.8mos. with Optune Lua +…

ByRidhi RastogiSeptember 16, 2025

Shilpa Biologicals and SPIMACO Bio Partner to Advance Access to PD-1 Inhibitor Biosimilars in MENA Region

Novocure Reports MHLW’s Approval of Optune Lua for NSCLC

Contact US

FOLLOW US